Asia News

Found 33,664 articles

• Curiox Biosystems Achieves Commercialisation and Fund Raising Success in North Asia with the Support of Cornerstone Investor, ZIG Ventures

  10/15/2019

  The investment shall be used to scale up and accelerate the commercialisation activities of CURIOX globally.

• Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson™

  10/15/2019

  Can-Fite BioPharma Ltd. announced it has completed patient enrollment in its Phase II study of Namodenoson in the treatment of NAFLD/NASH.

• Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution

  10/15/2019

  Celemics, provider of NGS target enrichment kits and innovative sequencing platforms, announced the release of a comprehensive NGS target enrichment workflow for clinical and translational research applications.

• MaxQ AI's Intracranial Hemorrhage (ICH) Software to be Integrated on Philips' Computed Tomography Systems

  10/15/2019

  MaxQ AI, the industry-leading medical diagnostic AI company, today announced that the company's Accipio intracranial hemorrhage (ICH) and stroke software will be integrated on Philips' computed tomography (CT) systems.

• Therapix Biosciences Announces Positive Data From Recent Pre-clinical Study for New Drug Candidate THX-210

  10/15/2019

  Therapix Biosciences Ltd. (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today positive results in its pre-clinical study evaluating THX-210, a proprietary novel pharmaceutical preparation containing non-psychoactive cannabinoid cannabidiol (CBD) and palmitoylethanolamide (PEA)

• Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting® 2019

  10/15/2019

  The FXR agonist TERN-101, currently in Phase 1 studies, demonstrates the potential for liver-enriched tissue distribution

• Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD

  10/15/2019

  Takeda Pharmaceutical Company Limited announced that it has entered into an agreement to divest a portfolio of select over-the-counter and prescription pharmaceutical assets in a number of Near East, Middle East and Africa countries within its Growth and Emerging Markets Business Unit to Acino for a total value in excess of $200 million USD.

• Pi-Cardia Appoints Prof. Jacques Séguin As Chairman

  10/14/2019

  Pi-Cardia Ltd. (www.pi-cardia.net), announced today the appointment of Prof. Jacques Séguin, former CoreValve Founder and CEO and serial medical device entrepreneur, as Chairman of its Board of Directors.

• I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China

  10/14/2019

  I-Mab Biopharma and MorphoSys AG announced that I-Mab has received Investigational New Drug clearances from the National Medical Products Administration of China to expand the ongoing phase II and III clinical trials of TJ202/MOR202, MorphoSys's human monoclonal anti-CD38 antibody for the treatment of multiple myeloma, also to mainland China.

• Chardan Healthcare Acquisition Corp. Announces Amendment to Merger Agreement with BiomX Ltd.

  10/14/2019

  Chardan Healthcare Acquisition Corp. (NYSE: CHAC, "CHAC"), a special purpose acquisition company ("SPAC") sponsored by affiliates of Chardan Capital Markets LLC ("Chardan") and BiomX Ltd. ("BiomX"), a microbiome company developing both natural and engineered phage therapies, announced that they entered into an amendment to their definitive agreement

• STA To Market Sarcoma Drug In Australia, New Zealand And SE Asia Following License Deal

  10/14/2019

  YONDELIS® (trabectedin) is a globally recognised treatment for patients with advanced soft tissue sarcoma as second-line therapy and beyond, but has been difficult for Australians to access

• Dr. Reddy's to release Q2 FY 20 results on November 1, 2019

  10/14/2019

  Dr. Reddy's Laboratories Ltd. will announce results for the second quarter ended September 30, 2019 on Friday, November 1, 2019 after the Board Meeting.

• Sun Pharma Launches CEQUA for the Treatment of Dry Eye Disease in the U.S.

  10/14/2019

  CEQUA™ (cyclosporine ophthalmic solution) 0.09% for topical ophthalmic use is the first and only approved cyclosporine treatment delivered with NCELL™ technology

• RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease

  10/11/2019

  RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced  full Week 52 results for all subjects in the previously announced positive Phase 3 randomized, controlled study of RHB-104 in Crohn’s disease (the “MAP US study”)

• Indonesia's Largest Single-payer System BPJS Kesehatan Teams up with Local Health Apps Startup Halodoc to Improve Equal Access to Health Care Across the Country

  10/11/2019

  The Healthcare & Social Security Agency (BPJS Kesehatan), the biggest single-payer system in Indonesia and in the world, officially signed a Memorandum of Understanding with Halodoc, the most innovative online-based integrated health technology application from Indonesia to develop digital-based health services

• Shionogi enters into a new license agreement and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.

  10/11/2019

  Shionogi & Co., Ltd. announced that it has entered into a new license agreement with Hsiri Therapeutics, Inc. regarding a collaborative research and development program to discover and develop additional novel therapeutics for non-tuberculous mycobacterial diseases and tuberculosis.

• Harbour BioMed Announces Completion of Phase 2 Study in China of HBM9036 In Patients With Moderate-to-Severe Dry Eye Disease

  10/11/2019

  Successful completion of Phase 2 monotherapy trial paves way for Phase 3 trials in China in early 2020

• Kangpu Biopharmaceuticals Successfully Completed Phase I Study of Novel CRL4-CRBN Modulator KPG-818 in the U.S.

  10/11/2019

  Kangpu Biopharmaceuticals announced that it has successfully completed a first-in-human phase I single ascending dose clinical study of KPG-818 conducted in the United States.

• CORRECTING and REPLACING Harbour BioMed Announces Completion of Phase 2 Study in China of HBM9036 In Patients With Moderate-to-Severe Dry Eye Disease

  10/11/2019

  Harbour BioMed (HBM) announced completion of a Phase 2 study in China of HBM9036 (tanfanercept), a new, investigational TNF receptor-1 fragment, in adult patients with moderate-to-severe Dry-Eye-Disease (DED).

• CMAB Biopharma and BJ Bioscience Establish an Exclusive Strategic Partnership

  10/11/2019

  The new partnership will combine the research and development ingenuity of BJ Bioscience with the state-of-art biologics manufacturing set up of CMAB